Zai Lab (ZLAB) Net Income towards Common Stockholders (2018 - 2026)
Zai Lab (ZLAB) posted Net Income towards Common Stockholders of -$51.0 million for Q1 2026, down 1.2% sequentially from -$50.4 million in Q4 2025, and down 5.32% YoY from -$53.9 million in Q1 2025.
Analysis
Zai Lab (ZLAB) Net Income towards Common Stockholders (2018 - 2026) Analysis & Trends
Zai Lab has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$51.0 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 5.32% year-over-year to -$51.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$178.1 million (up 29.34% YoY) and the FY2025 annual result came in at -$175.5 million, up 31.73% from the prior year.
- Net Income towards Common Stockholders retreated to -$51.0 million in Q1 2026 per ZLAB's latest filing, from -$50.4 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$36.0 million in Q3 2025 and troughed at -$161.2 million in Q3 2022.
- A 5-year average of -$74.2 million and a median of -$61.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The widest YoY moves for Net Income towards Common Stockholders: up 70.84% in 2022, down 67.19% in 2022.
- Over 5 years, Net Income towards Common Stockholders stood at -$61.8 million in 2022, then plunged by 54.49% to -$95.4 million in 2023, then increased by 14.4% to -$81.7 million in 2024, then surged by 38.29% to -$50.4 million in 2025, then declined by 1.2% to -$51.0 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$51.0 million, -$50.4 million, and -$36.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Zai Lab | 2.93 Bn | 2.23 Bn | 58.15 Mn | -50.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.83 Mn |
| Mar 31, 2026 | -51.02 Mn |
| Dec 31, 2025 | -50.41 Mn |
| Sep 30, 2025 | -35.96 Mn |
| Jun 30, 2025 | -40.73 Mn |
| Mar 31, 2025 | -48.44 Mn |
| Dec 31, 2024 | -81.68 Mn |
| Sep 30, 2024 | -41.67 Mn |
| Jun 30, 2024 | -80.28 Mn |
| Mar 31, 2024 | -53.47 Mn |
| Dec 31, 2023 | -95.43 Mn |
| Sep 30, 2023 | -69.15 Mn |
| Jun 30, 2023 | -120.90 Mn |
| Mar 31, 2023 | -49.14 Mn |
| Dec 31, 2022 | -61.77 Mn |
| Sep 30, 2022 | -161.19 Mn |
| Jun 30, 2022 | -137.93 Mn |
| Mar 31, 2022 | -82.39 Mn |
| Dec 31, 2021 | -211.83 Mn |
| Sep 30, 2021 | -96.41 Mn |